Diagnostic criteria in IBS: Useful or not?

Neurogastroenterology and Motility

Volumn 24, Issue 9, 2012, Pages 791-801

  Mearin, Fermín ^a   Lacy, Brian E ^b  

^a CENTRO MÉDICO TEKNON   (Spain)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Alarm features; Biomarkers; Diagnosis; Diagnostic criteria; Irritable bowel syndrome; Kruis; Los Angeles IBS; Manning; Rome

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; LACTOFERRIN; LEUKOCYTE ELASTASE;

ABDOMINAL RADIOGRAPHY; ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CRITERION VARIABLE; DIAGNOSTIC ACCURACY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; ENDOPHENOTYPE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; IRRITABLE COLON; LABORATORY TEST; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL;

CONSTIPATION; DIAGNOSIS, DIFFERENTIAL; DIARRHEA; HUMANS; IRRITABLE BOWEL SYNDROME; PRACTICE GUIDELINES AS TOPIC;

EID: 84865430465     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2012.01992.x     Document Type: Article

References (58)

1. Hungin AP, Whorwell PJ, Tack J, Mearin F. The prevalence, patterns and impact of irritable bowel syndrome: an international survey on 40000 subjects. Aliment Pharmacol Ther 2003; 17: 643-50.
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-21.
3. Longstreth GF, Wilson A, Knight K et al. Irritable bowel syndrome, health care use, and costs: a US managed care perspective. Am J Gastroenterol 2003; 98: 600-7.
4. Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 2004; 126: 1665-73.
5. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-91.
6. Dang J, Ardila-Hani A, Amichai MM, Chua K, Pimentel M. Systematic review of diagnostic criteria for IBS demonstrates poor validity and utilization of Rome III. Neurogastroenterol Motil 2012; 24: 853-e397.
7. Moayyedi P, Ford AC. Symptom-based diagnostic criteria for irritable bowel syndrome: the more things change, the more they stay the same. Gastroenterol Clin North Am 2011; 40: 87-103.
8. Jellema P, Van der Windt DA, Schellevis FG, Van der Horst HE. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care. Aliment Pharmacol Ther 2009; 30: 695-706.
9. Spiegel BM, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS expert. Am J Gastroenterol 2010; 105: 848-58.
10. Vincent C, Young M, Phillips A. Why do people sue doctors? A study of patients and relatives taking legal action. Lancet 1994; 343: 1609-13.
11. Spiegel BM, Gralnek IM, Bolus R et al. Is a negative colonoscopy associated with reassurance or improved health-related quality of life in irritable bowel syndrome? Gastrointest Endosc 2005; 62: 892-9.
12. Brandt LJ, Chey WD, Foxx-Orenstein AE et al. An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104(Suppl.): S1-35.
13. Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, Vakil NB, Simel D, Moayyedi P. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA 2008; 300: 1793-805.
14. Manning AP, Thompson WG, Heaton KW et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 277: 653-4.
15. Kruis W, Thieme CH, Weinzierl M et al. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984; 87: 1-7.
16. Drossman DA, Thompson WG, Talley NJ. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Int 1990; 3: 159-72.
17. Thompson WG, Longstreth GF, Drossman DA et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. II): II43-7.
18. Thompson WG. Gastrointestinal symptoms in the irritable bowel compared with peptic ulcer and inflammatory bowel disease. Gut 1984; 25: 1089-92.
19. Frigerio G, Beretta A, Orsenigo G, Tadeo G, Imperiali G, Minoli G. Irritable bowel syndrome: still far from a positive diagnosis. Dig Dis Sci 1992; 37: 164-7.
20. Vanner SJ, Depew WT, Paterson WG et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999; 94: 2912-7.
21. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 450-60.
22. Boyce PM, Koloski NA, Talley NJ. Irritable bowel syndrome according to varying diagnostic criteria: Are the new Rome II criteria unnecessarily restrictive for research and practice? Am J Gastroenterol 2000; 95: 3176-83.
23. Mearin F, Badía X, Balboa A et al. Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol 2001; 36: 1155-61.
24. Mearin F, Roset M, Badía X et al. Splitting irritable bowel syndrome: from original Rome to Rome II criteria. Am J Gastroenterol 2004; 99: 122-30.
25. Pimentel M, Hwang L, Melmed GY et al. New clinical method for distinguishing D-IBS from other gastrointestinal conditions causing diarrhea: The LA/IBS diagnostic strategy. Dig Dis Sci 2010; 55: 145-9.
26. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 2002; 97: 2812-9.
27. Cash BD, Rubenstein JH, Young PE et al. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology 2011; 141: 1187-93.
28. Spiegel BMR, DeRosa VP, Gralnek IM et al. Testing for celiac sprue in irritable bowel syndrome with predominant diarrhea: a cost-effectiveness analysis. Gastroenterology 2004; 126: 1721-32.
29. Fernández-Bañares F, Rosinach M, Esteve M, Forné M, Espinós JC, Maria Viver J. Sugar malabsorption in functional abdominal bloating: a pilot study on the long-term effect of dietary treatment. Clin Nutr 2006; 25: 824-31.
30. Fass R, Longstreth GF, Pimentel M et al. Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome. Arch Intern Med 2001; 161: 2081-8.
31. Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.
32. Biomarker Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
33. Mayer EA. The search for biomarkers and endophenotypes in functional gastrointestinal disorders. Gastroenterology 2011; 140: 1377-9.
34. Camilleri M. Scintigraphic biomarkers for colonic dysmotility. Clin Pharmacol Ther 2010; 87: 748-53.
35. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-45.
36. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103: 162-9.
37. Sidhu R, Wilson P, Wright A et al. Faecal lactoferrin - a novel test to differentiate between the irritable and inflamed bowel? Aliment Pharmacol Ther 2010; 31: 1365-70.
38. Lembo AJ, Neri B, Tolley J, Barken D, Carroll S, Pan H. Use of serum biomarkers in a diagnostic test for irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 834-42.
39. Sperber AD, Drossman DA. IBS: a multi-dimensional disorder cannot be understood or treated from a uni-dimensional perspective. Therap Adv Gastroenterol In press.
40. Whitehead WE, Crowell MD, Bosmajian L et al. Existence of irritable bowel syndrome supported by factor analysis of symptoms in two community samples. Gastroenterology 1990; 98: 336-40.
41. Taub E, Cuevas JL, Cook EW, Crowell MD, Whitehead WE. Irritable bowel syndrome defined by factor analysis. Dig Dis Sci 1995; 40: 2647-55.
42. Whitehead WE, Bassotti G, Palsson O, Taub E, Cook EC III, Drossman DA. Factor analysis of bowel symptoms in US and Italian populations. Dig Liver Dis 2003; 35: 774-83.
43. Talley NJ, Holtmann G, Agreus L, Jones M. Gastrointestinal symptoms and subjects cluster into distinct upper and lower groupings in the community: a four nations study. Am J Gastroenterol 2000; 95: 1439-47.
44. Thompson WG. Gender differences in irritable bowel symptoms. Eur J Gastroenterol Hepatol 1997; 9: 299-302.
45. Smith RC, Greenbaum DS, Vancouver JB et al. Gender differences in Manning criteria in the irritable bowel syndrome. Gastroenterology 1991; 100: 591-5.
46. Bijkerk CJ, De Wit NJ, Stalman WA, Knottnerus JA, Hoes AW, Muris JW. Irritable bowel syndrome in primary care: the patients' and doctors' views on symptoms, etiology and management. Can J Gastroenterol 2003; 17: 363-8.
47. Ringel Y, Williams RE, Kalilani L, Cook SF. Prevalence, characteristics, and impact of bloating symptoms in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2009; 7: 68-72.
48. Kamm MA, Müller-Lissner S, Talley NJ et al. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Am J Gastroenterol 2005; 100: 362-72.
49. Novick J, Miner P, Krause R et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
50. Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008; 103: 170-7.
51. Drossman DA, Chey WD, Johanson JF et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 329-41.
52. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008; 358: 2344-54.
53. Ford A, Brandt L, Young C et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009; 104: 1831-43.
54. Johnston JM, Kurtz CB, Macdougall JE et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology 2010; 139: 1877-86.
55. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 1582-91.
56. Wong RK, Palsson OS, Turner MJ et al. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol 2010; 1050: 2228-34.
57. Fernandez-Bañares F, Esteve M, Salas A et al. Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics. Am J Gastroenterol 2007; 102: 2250-8.
58. Limsui D, Pardi D S, Camilleri M et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis 2007; 13: 175-81.